

# Markus Moehler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9130715/publications.pdf>

Version: 2024-02-01

58

papers

8,338

citations

172457

29

h-index

138484

58

g-index

61

all docs

61

docs citations

61

times ranked

8687

citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	2.8	27
2	A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	3.2	4
3	Immunotherapy in Gastric Cancer. <i>Current Oncology</i> , 2022, 29, 1559-1574.	2.2	65
4	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€³). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	5.1	6
5	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. <i>British Journal of Cancer</i> , 2021, 124, 587-594.	6.4	79
6	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	1.6	122
7	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 27-40.	13.7	1,237
8	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2732.	2.4	8
9	Virotherapy in Germanyâ€”Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. <i>Viruses</i> , 2021, 13, 1420.	3.3	19
10	CXCR4 and hif-1Î± as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. <i>Acta OncolÃ³gica</i> , 2021, 60, 1543-1547.	1.8	1
11	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	1.6	45
12	Gastric cancer in autoimmune gastritis: A caseâ€”control study from the German centers of the staR project on gastric cancer research. <i>United European Gastroenterology Journal</i> , 2020, 8, 175-184.	3.8	30
13	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolimmunology</i> , 2020, 9, 1806680.	4.6	11
14	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <i>Annals of Oncology</i> , 2020, 31, 228-235.	1.2	60
15	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
16	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	3.6	40
17	Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing. <i>Frontiers in Oncology</i> , 2019, 9, 425.	2.8	13
18	Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i> , The, 2019, 393, 1948-1957.	13.7	1,494
20	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55.	2.6	24
21	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq1 1 0.284314 rgBT /Overl	2.8	33
22	Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). <i>European Journal of Cancer</i> , 2018, 93, 119-126.	2.8	33
23	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. <i>International Journal of Cancer</i> , 2018, 142, 1047-1055.	5.1	12
24	Evidence for <i><scp>PTGER</scp>4</i>,<i><scp>PSCA</scp>,</i> and <i><scp>MBOAT</scp>7</i> as risk genes for gastric cancer on the genome and transcriptome level. <i>Cancer Medicine</i> , 2018, 7, 5057-5065.	2.8	22
25	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	4.4	34
26	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	7.7	78
27	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 733-739.	2.3	13
28	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	13.7	984
29	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 342-359.	3.8	56
30	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. <i>Gastric Cancer</i> , 2017, 20, 358-367.	5.3	4
31	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	5.3	33
32	Chemotherapy for advanced gastric cancer. <i>The Cochrane Library</i> , 2017, 2017, CD004064.	2.8	662
33	Virotherapy Research in Germany: From Engineering to Translation. <i>Human Gene Therapy</i> , 2017, 28, 800-819.	2.7	19
34	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5671-5678.	7.0	121
35	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2389-2401.	2.0	36
36	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. <i>BMC Cancer</i> , 2016, 16, 699.	2.6	54

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	2.8	78
38	The Barrett's-associated variants at <i>GDF7</i> and <i>TBX5</i> also increase esophageal adenocarcinoma risk. Cancer Medicine, 2016, 5, 888-891.	2.8	21
39	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	3.6	34
40	Supportive evidence for <i>FOXP1</i> , <i>BARX1</i> , and <i>FOXF1</i> as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Medicine, 2015, 4, 1700-1704.	2.8	26
41	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	2.5	10
42	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 2015, 18, 550-563.	5.3	79
43	Moguntinones – New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics, 2014, 13, 1399-1409.	4.1	5
44	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. Frontiers in Oncology, 2014, 4, 92.	2.8	22
45	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. International Journal of Clinical Oncology, 2014, 19, 288-296.	2.2	11
46	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1065-1075.	10.7	1,479
47	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 2014, 14, 476.	2.6	8
48	Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. International Journal of Cancer, 2013, 132, 2548-2556.	5.1	32
49	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 490-499.	10.7	740
50	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. OncoTargets and Therapy, 2013, 6, 1119.	2.0	16
51	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World Journal of Gastroenterology, 2008, 14, 4156.	3.3	36
52	Multimodal treatment of gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 965-981.	2.4	35
53	(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. Digestive Diseases, 2004, 22, 345-350.	1.9	18
54	Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Therapy, 2003, 10, 477-480.	4.6	49

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 79-85.	1.4	14
56	Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 645-650.	1.4	17
57	Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-Fluorouracil. <i>Chemotherapy</i> , 2003, 49, 85-89.	1.6	8
58	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. <i>Cancer Gene Therapy</i> , 2001, 8, 158-167.	4.6	68